Increased serum concentrations of tissue inhibitor of metalloproteinase-1 in COPD patients

European Respiratory Journal

Volumn 25, Issue 5, 2005, Pages 885-890

  Higashimoto, Y ^a   Yamagata, Y ^a   Iwata, T ^a   Okada, M ^a   Ishiguchi, T ^a   Sato, H ^a   Masuda, M ^a   Itoh, H ^a  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Bronchial asthama; Chronic obstructure pulmonary disease; Exacerbation; Metallo proteinases; Serum markers; Tissue inhibitors of matrix metalloproteinases

Indexed keywords

CORTICOSTEROID; GELATINASE B; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ADULT; AGED; ARTICLE; ASTHMA; BLOOD SAMPLING; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; DISEASE CLASSIFICATION; DISEASE EXACERBATION; DISEASE SEVERITY; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SCORING SYSTEM; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

ADRENAL CORTEX HORMONES; AGED; ASTHMA; BIOLOGICAL MARKERS; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY FUNCTION TESTS; SMOKING; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 18744408209     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.05.00092804     Document Type: Article

References (29)

1. Ohnishi K, Takagi M, Kurokawa Y, Satomi S, Konttinen YT. Matrix metalloproteinase-mediated extracellular matrix protein degradation in human pulmonary emphysema. Lab Invest 1998; 78: 1077-1087.
2. Cataldo D, Munaut C, Noel A, et al. MMP-2- and MMP-9-linked gelatinolytic activity in the sputum from patients with asthma and chronic obstructive pulmonary disease. Int Arch Allergy Immunol 2000; 123: 259-267.
3. Kang MJ, Oh YM, Lee JC, et al. Lung matrix metalloproteinase-9 correlates with cigarette smoking and obstruction of airflow. J Korean Med Sci 2003; 18: 821-827.
4. Fujita J, Nelson NL, Daughton DM, et al. Evaluation of elastase and antielastase balance in patients with chronic bronchitis and pulmonary emphysema. Am Rev Respir Dis 1990; 142: 57-62.
5. Ogushi F, Hubbard RC, Vogelmeier C, Fells GA, Crystal RG. Risk factors for emphysema: cigarette smoking is associated with a reduction in the association rate constant of lung alpha 1-antitrypsin for neutrophil elastase. J Clin Invest 1991; 87: 1060-1065.
6. Montano M, Beccerril C, Ruiz V, Ramos C, Sansores RH, Gonzalez-Avila G. Matrix metalloproteinases activity in COPD associated with wood smoke. Chest 2004; 125: 466-472.
7. Mao JT, Tashkin DP, Belloni PN, Baileyhealy I, Baratelli F, Roth MD. All-trans retinoic acid modulates the balance of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in patients with emphysema. Chest 2003; 124: 1724-1732.
8. Vignola AM, Riccobono L, Mirabella A, et al. Sputum metalloproteinase-9/tissue inhibitor of metalloproteinase-1 ratio correlates with airflow obstruction in asthma and chronic bronchitis. Am J Respir Crit Care Med 1998; 158: 1945-1950.
9. Woessner JF Jr. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J 1991; 5: 2145-2154.
10. Beeh KM, Beier J, Kornmann O, Buhl R. Sputum matrix metalloproteinase-9, tissue inhibitor of metalloprotinease-1, and their molar ratio in patients with chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis and healthy subjects. Respir Med 2003; 97: 634-639.
11. Russell RE, Culpitt SV, DeMatos C, et al. Release and activity of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 by alveolar macrophages from patients with chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol 2002; 26: 602-609.
12. Bosse M, Chakir J, Rouabhia M, Boulet LP, Audette M, Laviolette M. Serum matrix metalloproteinase-9: tissue inhibitor of metalloproteinase-1 ratio correlates with steroid responsiveness in moderate to severe asthma. Am J Respir Crit Care Med 1999; 159: 596-602.
13. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 2001; 163: 1256-1276.
14. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. Am Rev Respir Dis 1987; 136: 225-244.
15. Seemungal TA, Donaldson GC, Bhowmik A, Jeffries DJ, Wedzicha JA. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 161: 1608-1613.
16. Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987; 106: 196-204.
17. Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbations. Chest 2000; 117: Suppl. 2, 398S-401S.
18. Sakai F, Gamsu G, Im JG, Ray CS. Pulmonary function abnormalities in patients with CT-determined emphysema. J Comput Assist Tomogr 1987; 11: 963-968.
19. Kohlhaufl M, Brand P, Rock C, et al. Noninvasive diagnosis of emphysema: aerosol morphometry and aerosol bolus dispersion in comparison to HRCT. Am J Respir Crit Care Med 1999; 160: 913-918.
20. Goddard PR, Nicholson EM, Laszlo G, Watt I. Computed tomography in pulmonary emphysema. Clin Radiol 1982; 33: 379-387.
21. Montuschi P, Kharitonov SA, Ciabattoni G, Barnes PJ. Exhaled leukotrienes and prostaglandin in COPD. Thorax 2003; 58: 585-588.
22. Riise GC, Larsson S, Lofdahl CG, Andersson BA. Circulating cell adhesion molecules in bronchial lavage and serum in COPD patients with chronic bronchitis. Eur Respir J 1994; 7: 1673-1677.
23. Cataldo DD, Gueders MM, Rocks N, et al. Pathogenic role of matrix metalloproteases and their inhibitors in asthma and chronic obstructive pulmonary disease and therapeutic relevance of matrix metalloproteases inhibitors. Cell Mol Biol (Noisy-le-grand) 2003; 49: 875-884.
24. Cataldo D, Munaut C, Noel A, et al. Matrix metalloproteinases and TIMP-1 production by peripheral blood granulocytes from COPD patients and asthmatics. Allergy 2001; 56: 145-151.
25. Hogg JC, Chu F, Utokaparch S, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004; 350: 2645-2653.
26. Retamales I, Elliott WM, Meshi B, et al. Amplification of inflammation in emphysema and its association with latent adenoviral infection. Am J Respir Crit Care Med 2001; 164: 469-473.
27. Winkler MK, Foldes JK, Bunn RC, Fowlkes JL. Implications for matrix metalloproteinases as modulators of pediatric lung disease. Am J Physiol Lung Cell Mol Physiol 2003; 284: L557-L565.
28. Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002; 57: 847-852.
29. Kikuchi K, Kadono T, Furue M, Tamaki K. Tissue inhibitor of metalloproteinase 1 (TIMP-1) may be an autocrine growth factor in scleroderma fibroblasts. J Invest Dermatol 1997; 108: 281-284.